StockData
Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc. (EVFM) stock

EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)

Close on Oct 19, 2026Market cap $865.23KP/E –Yield –

Evofem Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Evofem Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$2.76M. For fiscal 2025 it was $3.37M. The highest annual figure on record is $3.37M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.37M–
FY2024Dec 31, 2024-$7.68M–
FY2023Dec 31, 2023-$17.85M–
FY2022Dec 31, 2022-$84.12M–
FY2021Dec 31, 2021-$166.80M–
FY2020Dec 31, 2020-$103.62M–
FY2019Dec 31, 2019-$52.74M–
FY2018Dec 31, 2018-$77.64M–
FY2017Dec 31, 2017-$35.69M–
FY2016Dec 31, 2016-$12.04M–
FY2015Dec 31, 2015-$42.05M–
FY2014Dec 31, 2014-$9.59M–
FY2013Dec 31, 2013-$14.42M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.49M–
Q1 FY2026Mar 31, 2026-$4.57M-1497.2%
Q4 FY2025Dec 31, 2025$3.35M–
Q3 FY2025Sep 30, 2025$951.00K–
Q2 FY2025Jun 30, 2025-$1.25M–
Q1 FY2025Mar 31, 2025$327.00K–
Q4 FY2024Dec 31, 2024-$1.00M–
Q3 FY2024Sep 30, 2024-$2.44M–
Q2 FY2024Jun 30, 2024-$1.39M–
Q1 FY2024Mar 31, 2024-$2.84M–
Q2 FY2023Jun 30, 2023-$7.34M–
Q1 FY2023Mar 31, 2023-$3.58M–
Q4 FY2022Dec 31, 2022-$12.05M–
Q3 FY2022Sep 30, 2022-$18.72M–
Q2 FY2022Jun 30, 2022-$24.42M–
Q1 FY2022Mar 31, 2022-$28.93M–
Q4 FY2021Dec 31, 2021-$37.42M–
Q3 FY2021Sep 30, 2021-$43.37M–
Q2 FY2021Jun 30, 2021-$41.14M–
Q1 FY2021Mar 31, 2021-$44.87M–
Q4 FY2020Dec 31, 2020-$35.85M–
Q3 FY2020Sep 30, 2020-$26.16M–
Q2 FY2020Jun 30, 2020-$22.37M–
Q1 FY2020Mar 31, 2020-$19.24M–
Q4 FY2019Dec 31, 2019-$12.87M–
Q3 FY2019Sep 30, 2019-$14.30M–
Q2 FY2019Jun 30, 2019-$11.94M–
Q1 FY2019Mar 31, 2019-$13.63M–
Q4 FY2018Dec 31, 2018-$14.98M–
Q3 FY2018Sep 30, 2018-$18.43M–
Q2 FY2018Jun 30, 2018-$23.24M–
Q1 FY2018Mar 31, 2018-$20.99M–
Q4 FY2017Dec 31, 2017-$15.35M–
Q3 FY2017Sep 30, 2017-$9.07M–
Q2 FY2017Jun 30, 2017-$6.36M–
Q1 FY2017Mar 31, 2017-$4.91M–
Q4 FY2016Dec 31, 2016-$1.98M–
Q3 FY2016Sep 30, 2016-$1.87M–
Q2 FY2016Jun 30, 2016-$2.52M–

More Evofem Biosciences figures

See a number that looks wrong?